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Abstract
Background: Though overexpression of epidermal growth factor receptor (EGFR) in several forms of cancer is
considered to be an important prognostic biomarker related to poor prognosis, clear correlations between
biomarker assays and patient management have been difficult to establish. Here, we utilize a targeting directly
followed by a non-targeting tracer-based positron emission tomography (PET) method to examine some of the
aspects of determining specific EGFR binding in tumors.
Methods: The EGFR-binding Affibody molecule ZEGFR:2377 and its size-matched non-binding control ZTaq:3638 were
recombinantly fused with a C-terminal selenocysteine-containing Sel-tag (ZEGFR:2377-ST and ZTaq:3638-ST). The proteins
were site-specifically labeled with DyLight488 for flow cytometry and ex vivo tissue analyses or with 11C for in vivo PET
studies. Kinetic scans with the 11C-labeled proteins were performed in healthy mice and in mice bearing xenografts
from human FaDu (squamous cell carcinoma) and A431 (epidermoid carcinoma) cell lines. Changes in tracer uptake in
A431 xenografts over time were also monitored, followed by ex vivo proximity ligation assays (PLA) of EGFR expressions.
Results: Flow cytometry and ex vivo tissue analyses confirmed EGFR targeting by ZEGFR:2377-ST-DyLight488.
[Methyl-11C]-labeled ZEGFR:2377-ST-CH3 and ZTaq:3638-ST-CH3 showed similar distributions in vivo, except for notably higher
concentrations of the former in particularly the liver and the blood. [Methyl-11C]-ZEGFR:2377-ST-CH3 successfully visualized
FaDu and A431 xenografts with moderate and high EGFR expression levels, respectively. However, in FaDu tumors, the
non-specific uptake was large and sometimes equally large, illustrating the importance of proper controls. In the A431
group observed longitudinally, non-specific uptake remained at same level over the observation period. Specific uptake
increased with tumor size, but changes varied widely over time in individual tumors. Total (membranous and
cytoplasmic) EGFR in excised sections increased with tumor growth. There was no positive correlation between total
EGFR and specific tracer uptake, which, since ZEGFR:2377 binds extracellularly and is slowly internalized, indicates a
discordance between available membranous and total EGFR expression levels.
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Conclusions: Same-day in vivo dual tracer imaging enabled by the Sel-tag technology and 11C-labeling
provides a method to non-invasively monitor membrane-localized EGFR as well as factors affecting
non-specific uptake of the PET ligand.
Keywords: Epidermal growth factor receptor, Affibody molecule, Sel-tag, Dual tracer imaging, Positron
emission tomography
Background
The overexpression of epidermal growth factor receptor
(EGFR) in many human tumors [1] has been related to
metastasis, therapy resistance, and poor prognosis [2].
Extracellular, intracellular, and mutated EGFRs have
been therapeutic targets in cancer for some time [3] and
the ability to quantify expression levels could be used to
identify patients that would benefit from anti-EGFR
therapies. However, poor correlations between conven-
tional assessments of EGFR expression and clinical re-
sponses have raised questions about whether it is the
assays that are inadequate or whether there are funda-
mental issues related to the in vivo function of EGFRs
that need to be considered [4]. Non-invasive nuclear
medicine-based molecular imaging of receptors can po-
tentially offer advantages over conventional biopsy-based
analyses since these methods provide global tumor as-
sessments that should be less prone to sampling errors.
Radiolabeled tracers ranging from small molecules up to
antibodies have been developed for EGFR imaging using
single photon and positron emission tomography
(SPECT and positron emission tomography (PET), re-
spectively) [5]. However, there is still no consensus on
the most appropriate radiotracer to use. Most of the
tracers studied have had issues concerning in vivo specifi-
city, selectivity, and/or sensitivity. In addition to variations
in non-targeting uptakes due to the varying characteristics
of individual tumors in which the receptor modeling is to
be performed, the imaging results have also been affected
by metabolism, limited bioavailability, and inappropriate
kinetics of the imaging probes [6].
Dual or paired tracer imaging has been used in neurore-
ceptor imaging since the mid-1980s to assess non-
targeting contributions to the signal of targeting radio-
tracers, but to a much less extent for receptor imaging in
tumors. Most of the studies pairing tracers in the same
tumor have either been performed in SPECT studies in
the brain or in preclinical optical imaging of surface tu-
mors [7]. We aimed here to examine some of the issues
reported in EGFR imaging by using a dual tracer imaging
strategy based on Affibody molecules and preclinical PET.
Affibody molecules are small size proteins (58 residues,
≈7 kDa) obtained by randomizing thirteen surface resi-
dues in the Affibody protein scaffold [8]. High-affinity
binders have been developed and evaluated for SPECT or
PET imaging of tumors [9]. Several probes targeting EGFR
have been developed [10, 11]. In particular, ZEGFR:1907 has
been labeled for preclinical SPECT (111In) and PET (64Cu,
18F) applications [12–14]. Subsequently, ZEGFR:2377, which
binds with equally high (subnanomolar) affinity to human
and murine EGFR, was developed so that the tracer be-
havior in rodents would be more analogous to that ex-
pected in humans [15]. ZEGFR:2377 was labeled with
111In
for SPECT studies, and EGFR-expressing tumors were
successfully imaged when the tracer specific activity was
appropriately adjusted to reduce competing uptake in
non-tumor tissues [16]. Fluorescently labeled targeting
and non-targeting Affibody molecules have also recently
been co-injected in preclinical fluorescence imaging stud-
ies in order to estimate and correct for non-specific con-
tributions to the EGFR expression levels determined with
the targeting Affibody molecule [17].
Here, we used small animal PET and short-lived, dual
targeting and non-targeting Affibody molecules to exam-
ine some of the parameters affecting the in vivo quantifi-
cation of EGFR receptors. We paired ZEGFR:2377 with a
size-matched control ZTaq:3638 (S1-1 in [18]) to perform
in vivo studies of binding to EGFR-expressing xeno-
grafts. To examine the ability of ZEGFR:2377 to detect dif-
ferent EGFR expression levels in tumors with varying
characteristics, we used two models (A431 (epidermoid
carcinoma) and FaDu (squamous cell carcinoma)) and,
in one series, examined changes in tracer uptake with
the growth of A431 tumors. Labeling was performed
with 11C (t1/2 = 20.4 min). This permitted observation in
vivo for 60 min, which is consistent both with the fairly
rapid clearance of ZEGFR:2377 [16] and the desirability for
performing “same-day” sequential imaging with the control
ZTaq:3638 in each individual. A Sel-tag (ST) containing a
selenocysteine residue within a C-terminal -Gly-Cys-Sec-
Gly sequence [19] was used for the rapid and site-specific
labeling with 11C, giving the radiotracers [methyl-11C]-
ZEGFR:2377-ST-CH3 and [methyl-
11C]- ZTaq:3638-ST-CH3.
Our results demonstrate the feasibility and potential advan-
tages of same-day in vivo dual tracer imaging of membrane
EGFR levels using 11C-labeled Affibody molecules and sug-
gest this PET approach to be useful for non-invasively
evaluating specific and unspecific retention of labeled
probes in peripheral tumors with varying target
expressions.
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Results
Preparation and labeling of the Sel-tagged Affibody
molecules
The Sel-tagged Affibody molecules were successfully ob-
tained by expression in E. coli as C-terminal fusions to
green fluorescent protein (GFP), then recovered with
immobilized metal ion affinity chromatography (IMAC),
released by tobacco etch virus (TEV)-protease cleavage,
and purified by high-performance liquid chromatography
(HPLC). Correct expected masses (7.267 and 7.157 kDa
for ZEGFR:2377-ST and ZTaq:3638-ST, respectively) were veri-
fied by electrospray ionization-mass spectroscopy.
Using the previously developed protocol [20], Affibody
molecules were 11C-labeled and purified within 50 min,
with decay-corrected yields up to 20 % based on used
[11C]methyl iodide (CH3I). Radiochemical purities were
95 ± 3 %, with labeled dimer occasionally detected. Ef-
forts were not made to increase the specific radioactivity
since an optimal rather than the highest possible specific
activity was required [13, 14, 16].
EGFR targeting by ZEGFR:2377 -ST but not ZTaq:3638-ST
In vitro and ex vivo assays were used to test whether the
C-terminal ST and labeling at the ST interfered with the
EGFR binding of ZEGFR:2377 (characterized in [16]). Flow
cytometry (Fig. 1a) showed ZEGFR:2377-ST-[DyLight488]
(red curves) clearly bound to A431 and less to FaDu, but
not at all to MDA-MB-453 cells (human breast carcinoma),
which correlated well with EGFR levels (western blot,
Fig. 1c). ZEGFR:2377-ST-[DyLight488] binding in A431 and
Fig. 1 a Cell-binding assay of non-blocked (red) and blocked (blue, tenfold ZEGFR:2377) ZEGFR:2377-ST-[DyLight 488] and controls ZTaq:3638-ST-[DyLight
488] (green) and DyLight 488 dye (black) using FACS analysis in A431 (left), FaDu (middle), and MDA-MB-453 (right) cells with high, medium, and
low/no expressions of EGFR, respectively. b Fluorescent microscopy images of tumor (A431), liver, and kidney. Fluorescence in the tumor is only
observed with the ZEGFR:2377 probe. High autofluorescence of the liver is observed with all probes. Fluorescence from both the ZEGFR:2377 and
ZTaq:3638 probes is observed in the kidney. c western blots of A431, FaDu, and MDA from cell (left) and tumor (right) lysates using an antibody
against human EGFR. The protein concentration of the cell lysates was determined by Bradford protein assay and Ponceau S staining of the membranes
was used as loading control. The arrow indicates full-length EGFR
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FaDu cells was significantly reduced by blocking with ex-
cess ZEGFR:2377 (blue curves). Non-targeting ZTaq:3638-ST-
[DyLight488] (green curves) showed no binding.
In vivo targeting ability was compared by analyzing
sections of tissues excised from mice that had been
injected with the fluorescently labeled Affibody mole-
cules. Fluorescence in the tumors was only detected with
ZEGFR:2377-ST-[DyLight488], indicating the probe’s cap-
ability for EGFR targeting in vivo (Fig. 1b, top panels).
Binding in the liver (Fig. 1b, middle panels) could not be
evaluated due to autofluorescence [21]. Fluorescence
from both tracers was observed in the kidneys (Fig. 1b,
lower panels), in agreement with renal elimination of
Affibody molecules [9].
In vivo biodistribution of [methyl-11C]-labeled ZEGFR:2377 –
ST-CH3 and ZTaq:3638-ST-CH3
Key features of the tracers’ distributions in healthy mice
during 60 min are shown in Fig. 2. The amount of pro-
tein injected was adjusted by spiking with unlabeled pro-
tein. Two protein amounts, 27 and 49 μg, were used in
accordance with previous studies [14, 16], to demon-
strate that the large uptake in the liver could be at least
partially blocked so tracer would be available for tumor
targeting. EGFR blocking was tolerated well with the
Affibody molecules, since they are antagonistic or
pharmacologically neutral [16]. Even after the partial
blocking, larger uptakes of [methyl-11C]-ZEGFR:2377-ST-
CH3 were still observed in the liver (Fig. 2a). The time-
activity curves (TACs) were very similar for the two
masses injected, and the standard deviations were simi-
lar to those of the non-spiked [methyl-11C]-ZTaq:3638-ST-
CH3 (Fig. 2b). Therefore, instead of the four individual
curves, one curve of the means of the four animals with
the standard deviations is shown here. Radioactivity in
the arterial and venous blood began to plateau after
40 min. Levels for [methyl-11C]-ZEGFR:2377-ST-CH3 were
higher than for [methyl-11C]-ZTaq:3638-ST-CH3. This ob-
servation is consistent with the binding of the targeting
ligand to shed or soluble EGFR, to smooth muscle cells
in the blood vessels and/or tracer dissociating from
EGFR receptors and returning to the circulation [16].
The higher uptake for the targeting ligand in the muscle
may be due to differences in blood radioactivity since
there are no or very low EGFR levels in skeletal muscle
and bone marrow.
Liver radioactivity plateaued after 30 min but was
30 % higher with [methyl-11C]-ZEGFR:2377-ST-CH3, since
the hepatic EGFR binding is not completely blocked at
these doses [14, 16]. Contributions from blood pool,
non-specific uptake, and/or tracer metabolism are re-

















Fig. 2 Biodistribution of [methyl-11C]-ZEGFR:2377-ST-CH3 and [methyl-
11C]-ZTaq:3638-ST-CH3 in healthy Balb/c mice (black lines ZEGFR:2377 and blue lines
ZTaq:3638 (means ± SD, n = 4 mice): a PET images (supine, summed from 30–60 min, 3-D volume rendering) and b time activity curves (SUV) in arterial
and venous blood, skeletal muscle, liver, and kidney over 60 min after injection
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highest radioactivity concentrations were found in the
kidneys and urinary bladder. The higher and slightly
earlier peak and a tendency to a faster renal washout ob-
served for [methyl-11C]-ZEGFR:2377-ST-CH3 may be due
to the added protein and/or the slightly more positive
charge of the control [22]. Low uptakes of radioactivity
were measured ex vivo in the lung, pancreas, spleen,
stomach, and intestines, but their relative amounts could
not be analyzed quantitatively in vivo in the mice due to
the influence of partial volume effects (PVEs).
In vivo tumor studies
Uptakes of [methyl-11C]-ZEGFR:2377-ST-CH3 in FaDu xe-
nografts were generally low (standardized uptake values
(SUV)mean = 0.64–1.22) and plateaued after 30 min
(Fig. 3a). Uptakes of the control (SUVmean = 0.68–0.79)
varied from one half to nearly the same levels as that of
the targeting protein. Uptake of [methyl-11C]-ZEGFR:2377-
ST-CH3 was heterogeneous in larger FaDu tumors
(Fig. 3b, left side). Even when areas with lower uptake
were excluded by thresholding, the SUVmean for the left
and right tumors in this animal only differed by ≈15 %.
Similar results were obtained for one of the other three
animals while the larger tumors in the two remaining
mice were too necrotic for reasonable comparisons of
uptakes between the xenografts. Phosphoimaging (PI) of
sections of excised tumors from Fig. 3b confirmed the het-
erogeneous distribution of the targeting tracer seen in the
PET images, in spite of immunohistochemistry (IHC)
staining results that indicated fairly homogenous EGFR
expressions (Fig. 4a, c vs. d, f ). High levels of carbonic
anhydrase IX (CAIX) immunostaining (Fig. 4b vs. e) indi-
cated the presence of large hypoxic areas.
In A431 xenografts, uptakes of [methyl-11C]-
ZEGFR:2377-ST-CH3 were higher than in FaDu (Fig. 4)
(SUVmean = 0.78–2.49) while uptakes of the control were
usually lower (SUVmean = 0.22–0.86; one particular out-
lier with SUVmean = 1.28). In one example (Fig. 5a), the
uptake of [methyl-11C]-ZEGFR:2377-ST-CH3 was ≈7 times
higher than that of [methyl-11C]-ZTaq:3638-ST-CH3. The
uptake of [methyl-11C]-ZEGFR:2377-ST-CH3 generally in-
creased with the tumor size (Fig. 5b) and appeared to be
homogenous in the size range studied here. Interestingly,
the SUVs were still increasing at 60 min, indicating that
equilibrium was not yet attained, while that of [methyl-
11C]-ZTaq:3638-ST-CH3 leveled off from 35 min. Perform-
ing acquisitions over more than 60 min to probe
whether the increases eventually leveled off was not pos-
sible due to the low counting statistics after three times





















































Fig. 3 PET images, summed 30–60 min, and TACs from a SCID mouse (prone) bearing tumors (white arrows): a one FaDu xenograft (1 × 106 cells,
12 days) or b two FaDu xenografts (left: (1 × 106 cells, 12 days); right: (0.5 × 106 cells, 12 days). Comparison A illustrates the higher uptake with
targeting [methyl-11C]-ZEGFR:2377-ST-CH3 but with a ≈60 % non-targeting uptake of [methyl-
11C]-ZTaq:3638-ST-CH3. Comparison B illustrates the visually
discernable heterogeneous uptake of the targeting Affibody in the larger tumor on the left. SUVmean is affected by whether the entire (1) or only
central ROI (2) of the left tumor is used
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Fig. 4 Ex vivo analyses of sections of the two tumors in Fig. 3b (left tumor (a–c); right tumor (d–f)). a, d Phosphoimaging of sections of
tumors excised immediately after the 60 min PET scan with [methyl-11C]-ZEGFR:2377-ST-CH3. b, e IHC detecting CAIX, staining was
performed on formalin-fixed, paraffin-embedded material using antibody against CAIX (BioScience, Slovakia) at a dilution 1:500. c, f IHC



















































Fig. 5 PET images, summed 30–60 min, and TACs from a Balbc nu/nu mouse (prone) bearing tumors (white arrows): a one A431 xenograft (1 × 107 cells,
15 days) or b two A431 xenografts (left: 1 × 107 cells, 28 days; right: 1 × 107 cells, 25 days). Comparison A shows a 7-times higher uptake with targeting
[methyl-11C]-ZEGFR:2377-ST-CH3 compared to the non-targeting [methyl-
11C]-ZTaq:3638-ST-CH3. Comparison B illustrates uptake of the targeting Affibody
increasing as the tumors grow from time from inoculation
Cheng et al. EJNMMI Research  (2016) 6:58 Page 6 of 15
In the longitudinal study of ten tumors in five mice
(growths as in Fig. 6a), the uptake of [methyl-11C]-
ZEGFR:2377-ST-CH3 equilibrated quickly when the tumors
were small but was still increasing at 60 min when the
tumors had grown larger (Fig. 6b, blue and green vs. red
curves), which suggests that the time of observation
needed until maximum uptake can vary with tumor de-
velopment. The uptake of [methyl-11C]-ZTaq:3638-ST-CH3
(0.6 ± 0.1) plateaued and did not, in this series, notably
change with tumor size (Fig. 6c). Grouping all scans for
the five mice and ten tumors together, the increasing
specific uptake (i.e., [SUVZEGFR:2377–SUVZTaq:3638]) cor-
related (exponential regression) with the number of days
from the time from inoculation for both SUVmean
(Fig. 6d, r2 = 0.73) and SUVmax (r
2 = 0.70, data not
shown). The variance was much greater in the correla-
tions to the xenograft volumes (SUVmean (Fig. 6e, expo-
nential regression, r2 = 0.27 (the largest tumor was here
treated as an outlier and excluded from the plot)) and
SUVmax (r
2 = 0.38, data not shown)), indicating the cor-
relation to be quite poor. However, several PET studies
were performed longitudinally in this study, which took
advantage of the strength of in vivo imaging for observ-
ing changes on the level of each individual tumor instead
of analysing by group that is typical of most ex vivo
studies. It was obvious from the monitoring over time
that changes in the SUVs were somewhat different for
each xenograft. There was a sharp increase in SUVs
between the first and second imaging in the very small
xenografts, but, as they grew larger, the incremental
SUV changes between the second and third experiments
were smaller or, in some cases, even decreased (Fig. 6f ).
Proximity ligation assay (PLA) analyses of all the sec-
tions of six of the harvested tumors showed positive and
negative areas with membranous (Fig. 7a, arrows) as well
as cytoplasmic (Fig. 7a arrowheads) EGFRs detected.
The PLA signals in the tumor sections were generally
greater in tumors of larger volumes, but there was quite
a large variance and therefore the correlation is consid-
ered poor (Fig. 7b, linear regression, r2 = 0.29). There
was, however rather clearly, a negative relation between
the PLA signals and the SUVs measured on the final
PET imaging day (Fig. 7c, linear regression, r2 = 0.74).
Discussion
This study is, to our knowledge, the first longitudinal in
vivo study in tumor xenografts using a radiolabeled EGFR-
binding tracer combined with an analogously labeled size-
matched control. The short-lived 11C radionuclide enabled
same day, paired imaging in each individual tumor. There-
fore, the protocol could minimize influences on the results
due to changing tumor characteristics over time (compared
to when studies are instead performed on same xenograft
on different days) or from differing characteristics of differ-
ent xenografts (when the comparisons are instead per-
formed in different animals). The Sel-tag enabled labeling
at the same site with fluorescent and radioactive labels,
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Fig. 6 Data from the longitudinal study of A431 xenografts: a Changes in tumor volumes with the days since inoculation. b TACs of the differing
uptakes in one A431 xenograft of [methyl-11C]-ZTaq:3638-ST-CH3 (black curve, day 8) and targeting [methyl-
11C]-ZEGFR:2377-ST-CH3 (red, blue, and
green curves on days 8, 19, and 21, respectively). c SUVmean for the uptake of [methyl-
11C]-ZTaq:3638-ST-CH3 measured in the A431 tumors vs. days
since inoculation. d Variations in specific uptake (SUVmean(ZEGFR:2377)–SUVmean(ZTaq:3638)) with the growth of all ten xenografts from inoculation.
e Variations in specific uptake (SUVmean of ZEGFR:2377–SUVmean of ZTaq:3638) of all ten xenografts as their volumes increased. f Variations in specific
uptake, SUVmean, in individual xenografts as their volumes increased
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capabilities in vitro, ex vivo, and in vivo. Labeling was fast,
and yields obtained even with 11C were sufficient for the
intended use. ZEGFR:2377 had an appropriate affinity and size
to quickly distribute from the circulation to the tumor. The
results obtained using this dual tracer protocol revealed
that the non-specific uptake should be evaluated, especially
when receptor levels are low and influences on tracer be-
havior from other tumor characteristics are comparatively
large, and that EGFR levels targeted by a membrane-
binding radioligand do not directly correlate to the total
(extra- plus intracellular) levels.
ZEGFR:2377 and ZTaq:3638 were expected to distribute
similarly since they are essentially the same size, charges
at physiological pH are nearly neutral and differ only by
two (two more lysines in ZTaq:3638), and they have an
equal number of hydrophobic acids and essentially the
same hydropathicity (Affibody AB, personal communica-
tion). Differences were, however, observed in their con-
centrations in blood and several organs in vivo, which
were interpreted to be primarily related to ZEGFR:2377
binding to peripheral EGFR. If receptor binding is to be
quantified with PET, an input function based on either
radioactivity in arterial blood or a reference region de-
void of receptors is needed [23]. For such studies, it will
be important to determine the identity of the radioactiv-
ity in the blood. At least part of the ZEGFR:2377-related
radioactivity in blood delivered to the tumors after 50–
60 min apparently has EGFR-binding capability, since its
uptake, but not that of the control, continued to increase
in the larger A431 tumors (Figs. 5 and 6b, c). Blood sam-
pling with subsequent analyses coupled to image-derived
blood curves could determine how much of (and when)
the radioactivity is intact, free, or bound tracer. These
studies are, however, preferably performed in larger ani-
mals since the very small blood volumes in mice limit
both the sampling frequency and volumes that can be
taken for the analyses.
Affibody molecules are ≈7 kDa in size. Even though
enhanced permeability and retention (EPR) properties of
tumors are primarily utilized to enhance delivery of
drugs >40 kDa, smaller proteins are also more extrava-
sated in highly vascularized tumors and retained longer
due to their impaired lymphatics [24]. The control pro-
tein, [methyl-11C]-ZTaq:3638-ST-CH3, distributed immedi-
ately (the vascular input) to both tumors studied here,
but additional increases in uptake over ≈30 min (see e.g.
Figs. 3a and 5b) suggest a passive EPR-related retention
also of these small proteins during the 1-hr observation
period. The non-specific uptake could sometimes be
relatively high; it varied between tumor models and was
not always the same for xenografts of the same cell line.
Both FaDu and A431 xenografts are highly angiogenic
[25, 26], and new blood vessels therefore grow rapidly
and eventually become disorganized, dilated, and leaky.
There are considerable inter- and intratumoral heteroge-










































Fig. 7 In situ PLA analyses of EGFR in formalin-fixed, paraffin-embedded sections of A431 xenografts from the longitudinal study. a EGFR-positive
tissue, magnification ×20. White arrows and arrowheads indicate membranous and cytoplasmic patterns of EGFR immunostaining, respectively.
Red dots: EGFR single proteins, blue: Hoechst nuclear staining, and green: auto fluorescence. b PLA signal counts/cell (relative EGFR expression
level) in EGFR positive sections vs. volumes of the excised tumors. c Specific tracer uptake on the last day of imaging vs. the PLA signal counts/
cell in excised tumor sections
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angiogenic states [27]. Contributions to tracer behavior
from non-specific uptake due to the vascular properties
in individual tumors need to be accounted for since they
may be quite large and may change over time and dur-
ing therapy [28]. This was simplest done here (in
Fig. 6d–f ) by subtracting the TACs of the non-targeting
ligand from that of the targeting to give a measure of
the specific uptake. Compartmental modeling can be
used to further quantify the binding and non-specific
uptakes (e.g., [29, 30] reviewed in [7]). However, TACs
from several of these studies (e.g., Figs. 5 and 6b) indi-
cate that the uptake of the targeting tracer did not al-
ways reach equilibrium during the 1-hr scan (the limit
for the observation time due to the short half-life of 11C).
Mathematical models can be used to quantify irreversibly
binding tracers, but they would require an input from ar-
terial plasma [31], which, as discussed above, is far more
readily sampled in animals larger than mice. Kinetic ana-
lyses of the uptakes of the probe labeled with a longer-
lived radionuclide might provide additional information
about if or when binding equilibrium is achieved. How-
ever, in this case, a same-day dual tracer approach to also
estimate the non-specific uptake could probably only be
done if, for example, the ligands were labeled with differ-
ent radionuclides and monitored with SPECT.
Other tumor characteristics will also affect quantifica-
tions of tracer uptakes. This is illustrated with the FaDu
xenografts imaged here. Here, uptakes of the targeting
tracer were low (consistent with low expression levels)
but were also visibly intra- and inter-tumorally heteroge-
neous. The uptake heterogeneity was inconsistent with
the fairly homogenous EGFR expressions shown by the
ex vivo IHC but could be consistent with the prominent
hypoxia levels detected (Fig. 4). Many experimental tu-
mors grow rapidly and quickly become hypoxic. Vessels
in hypoxic regions collapse due to increasing pressure in
growing tumors. A probe’s targeting ability in vivo will
thus be affected, since the number of functional vessels
delivering the probe has decreased and the distance the
probe must penetrate to target the cells has increased
[32]. Penetrability is expected to decrease as the size of
the probe increases, but these factors affect even the dis-
tribution of small (≤0.5 kDa) molecules. Although high
uptakes of Affibody molecules have been obtained in
tumors due to a favorable balance between their high af-
finity and smaller size compared to antibodies and frag-
ments, [33] hypoxia and collapse of vessels due to
increasing pressure would clearly contribute to a dispar-
ity between the total receptor levels and those measured
by the in vivo imaging tracers.
In the longitudinal A431 study, the uptake of the non-
targeting protein did not vary significantly, probably
because the tumors were still small and all inoculations
were from the same cell culture to minimize variations
in initial angiogenic status [34]. On the group level, the
specific uptake increased with time from inoculation
(Fig. 6d). However, on the individual level, there was a
tendency for uptake to level off as sizes increased in sev-
eral of the tumors (Fig. 6f )). This has previously also
been observed with EGFR-targeting 15-kDa nanobodies
in larger A431 xenografts and was suggested to be due
to necrosis and/or decreasing penetration of the probe
[35]. However, the A431 tumors studied here were pur-
posefully kept small, and necrotic areas with heteroge-
neous tracer uptake were not discernible. According to
the PLA analyses, total EGFR levels tended to increase
with the size of tumors (Fig. 7b) but did not positively
correlate to increases in specific tracer uptake (Fig. 7c).
Previous studies have also reported that ex vivo assays of
EGFR expressions did not correlate with the in vivo up-
take of other targeting ligands (e.g., [36–38]). There are
a number of reasons why discrepancies could be ex-
pected [4]. For example, ex vivo assays are optimized so
maximum binding of the labeled probes can be obtained
in the excised sections and are not performed under the
same conditions that affect probe accessibility in vivo.
Also, they generally only sample a small part of the
tumor and are therefore not necessarily representative of
the whole tumor. On the other hand, in vivo tracer mea-
surements (like PET) of whole tumor volumes are affected
by tracer ability to overcome in vivo pharmacological bar-
riers in order to effectively bind. These techniques also
have much lower resolution, so all the details observable
with techniques like IHC and PLA are not discernible.
The PLA analyses performed here revealed that the
EGFRs in the tumors were localized on the membrane as
well as in the cytoplasm. ZEGFR:2377 binds to membranous
EGFR and is barely internalized in A431 during at least
5 hrs [16], although the degree of internalization may vary
depending on the tumor and time [15]. Since we only
monitored the 11C-labeled ZEGFR:2377-based probe during
a 1-hr scan, it was probably primarily binding to available
membranous receptors. Therefore, no correlation to the
total (membranous and cytoplasmic) expression levels re-
vealed with IHC and PLA techniques should be expected.
Receptors are not static systems. For example, fluxes
in the levels of endogenous ligands influence the recep-
tors that are available for binding by radioligands as well
as by receptor-targeting pharmaceuticals. Ligand/recep-
tor interactions can lead to changes in the localization of
the receptors. Influences of the endogenous ligand on
levels of dopamine receptors have been actively studied
with PET (e.g., [39]), and this is also an area of active
research on other neuroreceptor systems. The dynamics
of receptor availability are likewise very important in
many aspects of cancer research. EGFR dimerization, in-
ternalization, receptor down-regulation, and degradation
are all major determinants of the nature and duration of
Cheng et al. EJNMMI Research  (2016) 6:58 Page 9 of 15
the receptor signaling [40]. Differences in the membran-
ous vs. cytoplasmic locations of EGFRs have been sug-
gested to be associated with tumorigenesis and a
prognostic factor for overall survival (e.g., [41, 42]). The
availability of appropriate in vivo imaging tools could be
very valuable for probing these differences in order to
better understand factors affecting the dynamics of the
receptor cyclisations, similar to studies performed in
neuroreceptor PET. Furthermore, many anti-EGFR
drugs target the membranous receptor. Therefore, im-
aging probes that monitor the availability of these targets
can be important for making prognoses about who
would benefit from these therapeutic strategies. It has
been suggested that EGFR status in vivo might be stud-
ied in serial biopsies of normal and tumor tissues [4].
We suggest instead that this serial dual Affibody-based
tracer imaging technique, possibly in tandem with
tracers such as 11C-labeled erlotinib [43] that target the
EGFR tyrosine kinase domain (and therefore estimate
the receptors in both the membrane and cytoplasm),
could provide non-invasive methods for studying
changes in numbers and locations of receptors during
tumor growth and EGFR cycling.
Conclusions
This study demonstrated the feasibility of using a dual
PET tracer strategy using EGFR-targeting [methyl-11C]-
ZEGFR:2377-ST-CH3 followed by the size-matched control
[methyl-11C]-ZTaq:3638-ST-CH3 to study EGFR levels and
examine underlying factors contributing to the imaging
read-out. Though the specific uptake did differ for tu-
mors with different EGFR expression levels, the uptakes
were also affected to different degrees by factors in the
tumor architecture limiting their access and non-specific
uptake mechanisms, as well as whether the EGFRs to be
quantified are localized extra- or intracellularly. This
tracer pair appears promising for further applications as
investigational imaging biomarkers in PET studies of
fluctuations in accessible membrane EGFRs.
Methods
DNA constructions and expression of Sel-tagged Affibody
molecules
The EGFR-binding Affibody molecule ZEGFR:2377 [15, 16]
and the irrelevant Taq polymerase-binding Affibody
molecule ZTaq:3638 [18] were fused with a C-terminal ST
as previously described [19, 44]. Gene segments encod-
ing a hexahistidyl tag (H6), GFP, and a cleavage site for
TEV-protease were introduced upstream of the Affibody
molecules using polymerase chain reaction (PCR), to en-
code the constructs H6-GFP-TEV-ZEGFR:2377-ST and H6-
GFP-TEV-ZTaq:3638-ST. Sequence-confirmed plasmids
were transformed to BL21(DE3) cells (Novagen) already
harboring the pSUABC plasmid [45]. The two fusion
proteins were expressed in shake flasks (LB medium
supplemented with 50 μg/mL kanamycin and 34 μg/mL
chloramphenicol. Gene expression was induced by add-
ing isopropyl β-D-1-thiogalactopyranoside to a final con-
centration of 0.5 mM. L-Cysteine and selenite were
added to the cultures to a final concentration of 1 μM
and 5 nM, respectively, and cultivations were continued
overnight at 25 °C. Cells were harvested by centrifuga-
tion at 5,000 rpm and disrupted by sonication followed
by centrifugation 16,000 rpm, 20 min, 4 °C. The two fu-
sion proteins were purified by IMAC on a HisTrap FF
column (GE Healthcare) and eluted with 50 % tris(hy-
droxymethyl)aminomethane hydrochloride (Tris)-HCl
buffer, 50 mM, pH 8.0, containing 500 mM imidazole.
Buffer was exchanged to TEV cleavage buffer (50 mM
Tris-HCl pH 8, 0.5 M ethylenediaminetetraacetic acid
(EDTA), 1 mM dithiothreitol (DTT)) by dialysis prior to
digestion by TEV protease overnight at 4 °C using 50-
times excess of a His-tagged TEV protease. Cleavage
mixtures were applied on IMAC columns, and Affibody
molecules were recovered in the flow-through. Protein
purity was assessed by SDS-PAGE analysis. ZEGFR:2377-
ST and ZTaq:3638-ST were further purified by reversed
phase chromatography using a Resource RPC 1-ml col-
umn (GE Healthcare), using the following buffer system:
buffer A, 0.1 % trifluoroacetic acid (TFA) in water, and
buffer B, 0.1 % TFA in acetonitrile. The protein was
eluted with a gradient of 5–50 % buffer B over 20 min.
Fluorescence labeling to produce ZEGFR:2377-ST- and
ZTaq:3638-ST-[DyLight488]
ZEGFR:2377-ST and ZTaq:3638-ST were labeled specifically
at the Sec residue using maleimide-activated DyLight
488 (Pierce). Briefly, Sel-tagged Affibody (30 μM) was
reduced with DTT (1 mM) at room temperature for
30 min and then incubated in the dark with DyLight 488
(2.5 mM, dimethylsulfoxide (DMSO)) for 30 min. DTT
(5 mM) was added to quench the reaction, and the
Affibody-ST-[DyLight488] was purified and desalted to
physiologically buffered saline (PBS) through a NAP-5
column (GE Healthcare). The concentration of the
ZEGFR:2377-ST-[DyLight488] or ZTaq:3638-ST-[DyLight488]
was determined spectrophotometrically using an extinc-
tion coefficient of 21,050 M−1cm−1 at 280 nm by a
Nanodrop (Thermo). The labeled proteins were stored
in the refrigerator without direct exposure to light.
11C-Labeling to produce [methyl-11C]- ZEGFR:2377-ST-CH3
and -ZTaq:3638-ST-CH3
The Sel-tagged Affibody molecules were 11C-labeled spe-
cifically at the Sec residue, by the method used previ-
ously [19, 20, 29, 46]. Briefly, the Sel-tagged Affibody
molecule was reduced with DTT (1 mM) at 35–37 °C
for ≥20 min. An aliquot (10–25 μl) of [11C]CH3
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(prepared as in [47] from cyclotron-produced [11C]CO2
(PETtrace, GE Healthcare)) and trapped in DMSO
(0.2 ml)) was added. After 20 min at 35–37 °C, the reac-
tion was quenched with DTT (5 mM) and the [methyl-
11C]-Affibody-ST-CH3 was desalted (NAP-5, PBS).
Radiochemical purity was analyzed by radio-HPLC
(Superdex Peptide 10/300 GL (GE Healthcare) and
eluted with PBS, using ultraviolet- (210 nm) and radio-
detectors in series).
Cell lines and animals
All cell lines were purchased from American Type Cul-
ture Collection and cultured at 37 °C, supplemented
with 5 % CO2 in a humidified environment. A431 and
FaDucells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) (4500 mg/L D-glucose containing L-
glutamine) whereas MDA-MB-453 was cultured in
DMEM (1000 mg/L D-glucose containing L-glutamine).
All media were additionally supplemented with 1 mM
sodium pyruvate, 100 units penicillin/mL, 100 μg
streptomycin/mL, and 10 % foetal bovine serum. Media
for FaDu cells were further supplemented with 0.1 mM
non-essential amino acids and 2 mM HEPES. EGFR
expression levels were confirmed using western blotting
(Fig. 1c). The integrity of the cell lines was verified with
short tandem repeat (STR) profiling cell authentication
analysis (LGC Standards).
Balb/c, SCID, and Balb/c (nu/nu) mice were pur-
chased from Charles River. The animals were housed
under standard conditions according to local regula-
tions, with access to food and water ad libitum in the
Department of Comparative Medicine at Karolinska
University Hospital, Solna.
Cell-binding assay using fluorescence-activated cell sorting
(FACS) analysis
Cells were trypsinized, washed with PBS containing 1 %
albumin, divided into 200 μl aliquots containing 300,000
cells, which were then incubated 1 h with 0.1 μM of either
ZEGFR:2377-ST-[DyLight488] or ZTaq:3628-ST-[DyLight488].
The labeled cells were subsequently separated from non-
bound tracer by centrifugation. PBS buffer was used as a
negative control. For blocking experiments, cells were
pre-incubated with 1 μM non-labelled ZEGFR:2377-ST for
5 min before adding 0.1 μM ZEGFR:2377-ST-[DyLight488].
After shaking for 1 h at room temperature, the cells were
washed with PBS containing 1 % albumin, suspended in
PBS and then analysed with a FACSort Calibur flow
cytometer (Becton Dickinson).
Ex vivo fluorescent imaging of liver, kidney, and xenograft
sections
A431 cells (107 in 0.15 ml PBS) were inoculated subcuta-
neously (s.c.) into the right flank of four mice (Balb/c,
nu/nu, female, 18–20 g, 10 weeks old). After 3 weeks,
the mice were injected intravenously (i.v.), in the tail
vein with either PBS, 60 μM Dylight 488 dye, 60 μM
ZEGFR:2377-ST-[DyLight488], or 60 μM ZTaq:3638-ST-
[DyLight488] (0.2 ml). Mice were sacrificed 1-h postinjec-
tion (p.i.), and tissues were excised, snap frozen (−78 °C),
and sectioned (25 μm) using a freezing microtome. The
fluorescence was documented using an Axio Observer.Z1
fluorescence microscope (Zeiss).
Western blotting
Western blotting was performed using fresh cell lysates
or snap frozen tumor tissue excised from the animal.
Briefly, cells or tumor was first homogenized with lysis
buffer (50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 150 mM
NaCl, 1 % Triton X-100) in the presence of protease in-
hibitor, and then three cycles of freeze-thawing were ap-
plied on the mixture. The insoluble components
including cell or tissue debris were removed by centrifu-
gation. The supernatant corresponding to 20 μg of total
protein was analyzed by western blotting (Life technol-
ogy) using an antibody against human EGFR (Santa
Cruz, sc-03, 1:200). The reaction product was detected
by enhanced chemiluminescence (Perkin Elmer).
Immunohistochemistry
Tissues were resected, fixed in 2 % buffered formaldehyde,
dehydrated, embedded in paraffin, and sectioned. The sec-
tions were then deparaffinized with xylene, rehydrated,
and microwaved and then incubated overnight with the
monoclonal primary antibodies diluted in 1 % (wt/vol)
BSA and visualized by standard avidin–biotin–peroxidase
complex technique (Vector Laboratories, Burlingame, CA,
USA). Counterstaining was performed with Mayer’s
hematoxylin. The antibody against EGFR (Sigma, Sweden)
was used at a dilution 1:800, and the antibody against
CAIX (BioScience, Slovakia) was used at 1:500.
Phosphoimaging
After the mice were sacrificed, tumors were removed
and immediately frozen in dry ice and sectioned using
a cryomicrotome (CM 3050S, Leica Microsystems,
Wetzlar, Germany) with a thickness of 25 μm. The
sections were exposed on phosphor imaging plates for
at least 1 hour. Scanning was performed using a Ty-
phoon FLA 7000 (GE Healthcare).
Proximity ligation assays
The PLA protocol [48–50] is the standard procedure by
which the in situ PLA assay is performed at the proteo-
mics facility, Uppsala, Sweden (http://www.scilifelab.se/
facilities/pla-proteomics) and was followed according to
manufacturers’ instructions (Olink Bioscience, Uppsala,
Sweden). Briefly, formalin-fixed paraffin-embedded tumor
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tissue sections (4 μm) were deparaffinised, and the anti-
gen retrieval procedure was performed according to
protocol using 1xTarget retrieval solution citrate pH 6
(Dako art, S2369). After blocking, tumor sections
were incubated over night (4 °C) with primary
antibodies EGFR (D38B1) XP® Rabbit mAb #4267
(Cell Signalling) and mouse monoclonal EGFR (E3138,
Sigma-Aldrich), diluted 1:800 with Duolink diluent
solution (Sigma-Aldrich). After incubation, the slides
were washed in TBS-T, 2 × 5min.
PLA secondary probes anti-rabbit MINUS and anti-
mouse PLUS (Duolink kit, Sigma), containing the sec-
ondary antibodies conjugated with oligonucleotides,
were diluted 1:5 in Duolink antibody diluent. The sec-
ondary probe mixture (40 μl) was added to each sample,
and the slides were incubated in a humidity chamber for
1 h at 37 °C. The slides were washed in TBS-T, 2 × 5min.
Following the protocol, the ligation solution was added
to each sample, and the slides were incubated for
30 min at 37 °C. After incubation, the ligation solution
was tapped off, the slides were washed in TBS-T, and
40 μl of amplification solution was added to each sample
followed by incubation for 100 min at 37 °C. Hoechst
33342 dye nuclear staining (Life Technologies, H1399)
was added and incubated for 1 h at room temperature.
After washing in MQ water over night, 15 μl of Slow-
Fade Gold Antifade Reagent (Invirogen, S36936) was
added to each sample and covered with a cover slip. The
positive PLA signals were visualized as distinct red dots
in epifluorescence microscope Axioplan 2 (Zeiss).
Stacked TIFF images were acquired using Axiovision
4.8. Data analysis for in situ PLA images was performed
using the freeware Cell Profiler, developed by the Broad
Institute (http://www.cellprofiler.org). The data is given
in PLA signals/cell. For PLA signal quantification, three
images were taken of each section at ×20 magnification,
one each of positive (with high density of fluorescence
signals), one of the border between positive and negative
tissues, and one of negative tissue (with low concentra-
tion of fluorescence signals). The number of PLA signals
per image per single cell was estimated as a ratio be-
tween total fluorescence signal and total number of cells.
At less than two PLA signals per single cell, tissues were
counted as a negative.
PET data collection and processing
PET imaging was performed using a microPET Focus
120 scanner (CTI Concorde Microsystems, Knoxville,
TN, USA). List mode data, collected continuously over
60 min from the tracer injection, were reconstructed
using Ordered Subset Estimation Maximum in 2 dimen-
sions (OSEM2D) to increase the spatial resolution, with
a picture size of 256 × 256 pixels, four iterations, and 16
subsets. Data, normalized and corrected for randoms,
dead time, and radioactivity decay, were processed using
MicroPET Manager and evaluated using the Inveon
Research Workplace (IRW) software (Siemens Medical
Systems, Malvern, PA, USA). Venous and arterial ROIs
were delineated on the vena cava and left ventricle of
the heart, respectively, in the first frames of the scan.
Muscle ROIs were drawn on the right hamstring muscle
(images summed 0–60 min). ROIs of same shape and
size were drawn on the renal cortex and liver, on images
summed over periods of maximum uptake after the ini-
tial distribution, 10–20 min p.i. Tumor ROIs were delin-
eated on images summed between 30 and 60 min and
thresholded ≈75 %, based on palpation and subsequent
post-mortem measurements. The IRW software calcu-
lated the SUVmean and SUVmax and their standard devia-
tions, along with the volumes of the ROIs (here called
the “image-derived volumes,” as opposed to those based
on measurements by palpations).
PET imaging of [methyl-11C]-ZEGFR:2377-ST-CH3 and
-ZTaq:3638-ST-CH3
All experiments involving animals were conducted in
accordance with the regulations of the Karolinska
Institutet and approved by the local laboratory animal
ethics committee (N325/09, N85/11, N416/12). Mice
were anesthetized (1.5 % isoflurane (Virbac) blended
with air (7:3) in a vaporizer (E-Z systems) delivered
through a Microflex non-rebreather mask (Euthanex
Corp)) and intravenously (i.v.) injected (tail vein) with
[methyl-11C]-Affibody-ST-CH3. Radioactivity in re-
gions of interest (ROIs) was calculated as mean and
maximum standardized uptake values (SUVmean and
SUVmax) normalized to body weight [51]. The uptake
of the non-targeting ligand was subtracted from that
of the targeting ligand as a measure of specific uptake
in some of the analyses.
For the biodistribution studies, Balb/c mice (female, 18–
20 g) were i.v. injected with [methyl-11C]-ZEGFR:2377-ST-
CH3 or [methyl-
11C]-ZTaq:3638-ST-CH3 (volume ≤0.2 ml).
Following previous studies on the effects of the adminis-
tering masses in the interval of 0.1–150 μg [16], the
masses of the ZEGFR:2377-based ligand were adjusted or
spiked with unlabeled ZEGFR:2377 to lower the specific ac-
tivity (here a total mass of 27 or 49 μg, (n = 2 each)). The
latter ZTaq:3638-based ligand (n = 4) was not spiked. The
necessity for adjusting the targeting protein mass to re-
duce non-tumor uptake so tumors could be visualized was
confirmed in two FaDu-bearing mice (Additional file 1:
Figure S1). Thereafter, for studies in the tumor-bearing
mice, the protein in the radiolabeling vial was adjusted so
the mass of targeting tracer injected would be 50–100 μg,
in accordance with the recommended dose interval previ-
ously established in [16].
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In the first pilot studies, mice with single and double
inoculations of FaDu and A431 cells were studied.
Imaging was performed with both the targeting and
non-targeting tracer, except in the doubly inoculated
FaDu-bearing mice. In those mice, only investigations
with [methyl-11C]-ZEGFR:2377-ST-CH3 were performed to
see if the uptakes would follow the growth of the
tumors. When this was found to not to be the case, only
the A431 tumors were chosen for the longitudinal study.
For the study of tumors with low/intermediate EGFR
expression, FaDu cells were injected subcutaneously
(s.c.) in SCID mice (male, 18–29 g, single inoculations,
n = 4 mice, with 1 × 106 cells; double inoculations, n = 4
mice, with 1 × 106 and 0.5 × 106 cells on the left and
right shoulders, respectively). FaDu xenografts grow very
rapidly once they have established, and for this reason,
the sizes of the xenografts were varied by performing the
double inoculations on the same day, but with different
numbers of cells. After 12–13 days, PET imaging was
performed with [methyl-11C]-ZEGFR:2377-ST-CH3 and, for
mice with single xenografts, ≥3.5 h later with [methyl-
11C]-ZTaq:3638-ST-CH3. The time interval between the
two investigations was chosen in order to allow suffi-
cient time (≥8 half-lives) for the decay of the radioactiv-
ity from the previous investigation. Tumors excised after
sacrifice were prepared for analyses by PI and IHC.
A431 cells (high EGFR expression) were injected
s.c. in Balb/c, nu/nu mice (female, 16–24 g, single in-
oculation in four mice, 107 cells; two inoculations in
five mice, 3 days apart to allow the mice to recover
between inoculations, first on the left and then on
the right shoulder, 107 cells each time). A431 xeno-
grafts grow more slowly than FaDu, and therefore, tu-
mors at different stages of development could be
observed by spreading out the interval between the
first and second inoculations. PET imaging was
performed with [methyl-11C]-ZEGFR:2377-ST-CH3 and
≥3.5 h later [methyl-11C]-ZTaq:3638-ST-CH3. Scanning
started from when the xenografts were palpable
(≥8 days) and thereafter, in the longitudinal study, 2–
11 days between the scanning sessions, depending on
xenograft development. Restricted by logistics and the
scans allowed by the ethical permission, two to five
scans/animal were performed. Details are given in the
Additional file 2: Table S1. Excised tumors were subse-
quently prepared for analyses by PI, IHC, and/or PLA.
Statistics
Imaging results are presented as values ± SD, if not
otherwise specified. Deviations of the measured values
from fitted lines were estimated using the Pearson’s cor-
relation coefficient, r2, ranging from 0–1, where 1 is a
total positive and 0 is no correlation between the vari-
ables X and Y.
Additional files
Additional file 1: Figure S1. PET image, summed 40–60 min, of the
uptake of targeting [methyl-11C]-ZEGFR:2377-ST-CH3 in one SCID mouse
(prone) bearing one s.c. FaDu tumor (1 × 106 cells, 13 days). Only 16-μg
protein was injected and nearly all radioactivity localized very quickly in
the liver giving SUV mean >2.5 times larger than for animals receiving
spiked tracer injections. The tumor (white arrow) was barely discernible
with a faint vascular signal. Even radioactivity distributing to the kidneys
and urinary bladder during the 60 min was markedly reduced. Thereafter,
the amount of protein administered was adjusted to 50–100 mg to partially
block the hepatic uptake and free the ligand for tumor targeting, as discussed
in the text. (PPTX 422 kb)
Additional file 2: Table S2. Imaging information and growth details of
the A431 tumors included in the longitudinal study. (DOCX 17 kb)
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